UBS reiterated a Buy rating on Medivation (NASDAQ: MDVN), and raised the price target to $148.00 (from $145.00), following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Stifel Reiterates Buy on Medivation (MDVN) Following Talazoparib Acquisition August 25, 2015 8:45 AM Wedbush Cuts Price Target on BioMarin Pharma (BMRN) Following Announced Sale of Talazoparib to Medivation (MDVN) August 25, 2015 6:55 AM Market Wrap: Markets Riled on China Worries; Apple's Cook Calms Investors; Southern Co. Bets on Nat GasAugust 24, 2015 5:18 PM RBC Capital Positive on BioMarin Pharma (BMRN) Following Talazoparib Sale (MDVN)August 24, 2015 10:29 AM Notable Mergers and Acquisitions 8/24: (SO)/(GAS) (MDVN)/(BMRN) (CIE) (MRKT) (DVA)August 24, 2015 9:46 AM Medivation (MDVN), BioMarin (BMRN) Enter Asset Purchase Agreement Covering Talazoparib August 24, 2015 7:01 AM Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarinAugust 24, 2015 7:00 AM Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarinAugust 24, 2015 7:00 AM